Skip to main content
. Author manuscript; available in PMC: 2014 Jul 8.
Published in final edited form as: Cancer Immunol Res. 2014 Jun;2(6):510–517. doi: 10.1158/2326-6066.CIR-14-0072

Figure 2.

Figure 2

Understanding TME composition for personalized combination of immunotherapeutic agents. Left, expression of VISTA, CD8, and CD11b was codetected in formalin-fixed paraffin-embedded tissue sections of colon and lung cancer tumor lesions. In these merged image panels, colocalization of VISTA (green) and CD11b (magenta) signal appears white. Right, tailored approach for tumor expressing PDL1 and VISTA in different cellular compartments of the TME. VISTA and PDL1 interfere with different subsets of CTL and distinctly affect their activities. Synergistic effects of dual VISTA and PDL1 blockade would be expected to enhance CTL and activities and boost antitumoral immunity.